A tighter archive for life-science signals.
Search once, then narrow by source or topic.
EpiBiologics raises $107M for its protein-degrading cancer drug
EpiBiologics raises $107M for its protein-degrading cancer drug
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs
GSK, Ionis claim study success for RNA-based hepatitis B drug
GSK, Ionis claim study success for RNA-based hepatitis B drug
Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug
Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug
5 FDA decisions to watch in the first quarter of 2026
5 FDA decisions to watch in the first quarter of 2026
Alumis soars as TYK2 drug hits mark in psoriasis trials
Alumis soars as TYK2 drug hits mark in psoriasis trials
Amgen buys protein-degrading startup Dark Blue for up to $840M
Amgen buys protein-degrading startup Dark Blue for up to $840M
CDC, following Trump’s orders, weakens US stance on childhood vaccinations
CDC, following Trump’s orders, weakens US stance on childhood vaccinations
Surfing the AI wave: How pharma can harness agents in ERP
Surfing the AI wave: How pharma can harness agents in ERP
Moderna, searching for a rebound, to seek approval of mRNA flu shot
Moderna, searching for a rebound, to seek approval of mRNA flu shot
Zenas shares crash after top drug misses expectations in immune disease study
Zenas shares crash after top drug misses expectations in immune disease study
Novo launches Wegovy pill; Argenx to swap CEOs
Novo launches Wegovy pill; Argenx to swap CEOs
10 clinical trials to watch in the first half of 2026
10 clinical trials to watch in the first half of 2026
Strategic diagnostic testing partnerships are accelerating clinical research
Strategic diagnostic testing partnerships are accelerating clinical research
Novo Nordisk’s weight loss pill approved by FDA
Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. By signing up to receive our newsletter,...
Biopharma CEO optimism is wavering in the US
Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. By signing up to receive our newsletter,...
Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump
Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump
Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug
Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page